Global Blood Therapeutics, Inc.

Shahul Nilar

Zhe Li

Qing Xu

Calvin Wesley Yee

Peter Michael Rademacher

Carsten Alt

Ming Yu

Lina Quattrocchio Setti

Manuel Zancanella

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

Cycloalkyl pyrimidines as ferroportin inhibitors

The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I: and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators

Growing community of inventors

Foster City, CA, United States of America

Shahul Nilar